

# Lauren E Walker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4228452/publications.pdf>

Version: 2024-02-01

16  
papers

291  
citations

1306789

7  
h-index

1125271

13  
g-index

18  
all docs

18  
docs citations

18  
times ranked

530  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. <i>Epilepsia</i> , 2022, 63, e1.  | 2.6 | 17        |
| 2  | Triple antithrombotic therapy and dual therapy – What is the evidence base?. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3009-3012.  | 1.1 | 1         |
| 3  | Pharmacokinetics of 5'-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2022, 75, e525-e528.       | 2.9 | 9         |
| 4  | A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1105-1113.  | 0.8 | 1         |
| 5  | 132...One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings. , 2021, , .   |     | 1         |
| 6  | The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite 5'-d-N4-hydroxycytidine in human plasma and saliva. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 206, 114356. | 1.4 | 45        |
| 7  | Avoiding harm from overprescribing: What are the challenges and how do we overcome them?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 6-8.   | 1.1 | 4         |
| 8  | Long-term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4877-4879.   | 1.1 | 3         |
| 9  | Concise advice: Introducing a new clinically focused BJCP series on evidence-based (de)prescribing in challenging situations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4484-4487.   | 1.1 | 0         |
| 10 | Sodium-glucose cotransporter-2 inhibitors in the non-diabetic heart failure patient. <i>British Journal of Clinical Pharmacology</i> , 2021, , .   | 1.1 | 0         |
| 11 | TEMPORARY REMOVAL: Reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. <i>Journal of Hepatology</i> , 2018, , .   | 1.8 | 4         |
| 12 | Prospective clinical trials to investigate clinical and molecular biomarkers. <i>Epilepsia</i> , 2017, 58, 20-26.  | 2.6 | 12        |
| 13 | Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. <i>Journal of Clinical Investigation</i> , 2017, 127, 2118-2132.  | 3.9 | 90        |
| 14 | <sc>WONOE</sc> appraisal: Molecular and cellular biomarkers for epilepsy. <i>Epilepsia</i> , 2016, 57, 1354-1362.  | 2.6 | 81        |
| 15 | Immunomodulatory interventions for focal epilepsy syndromes. <i>The Cochrane Library</i> , 2013, , CD009945.   | 1.5 | 7         |
| 16 | 'Septrin psychosis' among renal transplant patients with <i>Pneumocystis jirovecii</i> pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1117-1119.  | 1.3 | 10        |